Voyager Therapeutics (VYGR) stock price, revenue, and financials

Voyager Therapeutics market cap is $225.5 m, and annual revenue was $171.13 m in FY 2020

$225.5 M

VYGR Mkt cap, 29-Jun-2022

$171.1 M

Voyager Therapeutics Revenue FY, 2020
Voyager Therapeutics Net income (FY, 2020)36.7 M
Voyager Therapeutics EBIT (FY, 2020)27.4 M
Voyager Therapeutics Cash, 31-Dec-2020104.4 M
Voyager Therapeutics EV125.2 M
Get notified regarding key financial metrics and revenue changes at Voyager TherapeuticsLearn more
Banner background

Voyager Therapeutics Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

17.3m14.2m10.1m7.6m104.4m171.1m

Revenue growth, %

(18%)

R&D expense

27.7m42.2m62.3m64.9m119.7m108.8m

General and administrative expense

9.9m13.3m19.7m33.8m36.3m35.0m

Operating expense total

37.6m55.5m82.0m98.7m156.1m143.7m

EBITDA

(20.5m)(41.3m)

EBITDA margin, %

(118%)(290%)

EBIT

(20.3m)(41.3m)(71.9m)(91.1m)(51.7m)27.4m

EBIT margin, %

(117%)(290%)(709%)(1196%)(50%)16%

Interest expense

332.0k976.0k1.2m3.3m6.5m1.7m

Pre tax profit

(40.1m)(70.7m)(88.5m)(43.6m)36.7m

Income tax expense

52.0k(180.0k)

Net Income

(29.7m)(40.2m)(70.7m)(88.3m)(43.6m)36.7m

Voyager Therapeutics Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

31.5m46.9m86.0m104.4m

Accounts Receivable

826.0m

Prepaid Expenses

2.7m6.7m4.6m8.6m

Current Assets

195.9m178.8m171.8m162.5m304.7m197.8m

PP&E

3.2m7.9m10.3m12.8m18.0m25.4m

Total Assets

229.5m189.6m184.5m177.0m354.8m261.6m

Accounts Payable

612.0k550.0k1.0m1.0m4.1m634.0k

Short-term debt

3.2m4.2m

Current Liabilities

23.9m13.8m15.9m31.7m76.0m26.8m

Total Debt

3.2m4.2m

Total Liabilities

53.6m50.4m130.6m255.2m107.3m

Common Stock

32.0k32.0k37.0k37.0k

Preferred Stock

Additional Paid-in Capital

219.1m226.0m295.0m315.6m412.2m430.3m

Retained Earnings

(49.8m)(90.0m)(160.7m)(269.1m)(312.6m)(275.9m)

Total Equity

134.1m46.4m99.5m154.3m

Financial Leverage

1.4 x3.8 x3.6 x1.7 x

Voyager Therapeutics Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(3.8m)(40.2m)(70.7m)(88.3m)(43.6m)36.7m

Depreciation and Amortization

600.0k612.0k1.6m2.1m2.8m

Inventories

(234.0k)(847.0k)

Accounts Payable

950.0k(62.0k)470.0k(282.0k)2.6m(3.4m)

Cash From Operating Activities

(2.7m)(42.5m)(61.3m)(15.9m)48.7m(96.7m)

Purchases of PP&E

(1.0m)(5.0m)(4.0m)(4.3m)(7.7m)(12.1m)

Cash From Investing Activities

(194.8m)47.3m(3.7m)26.5m(90.5m)113.0m

Cash From Financing Activities

2.9m514.0k59.9m4.7m81.0m3.2m

Net Change in Cash

(5.1m)15.3m39.2m19.4m

Voyager Therapeutics Ratios

USDQ3, 2015

Financial Leverage

-3.5 x

Voyager Therapeutics Operating Metrics

FY, 2016

Patent Applications

28

Patents Issued

157

Voyager Therapeutics Employee Rating

2.723 votes
Culture & Values
3.8
Work/Life Balance
3.8
Senior Management
2.6
Salary & Benefits
3.9
Career Opportunities
3.4
Source